XTalks

AUGUST 17, 2020

To learn more about innovations in the field, Xtalks spoke to Anish Suri, PhD, president and chief scientific officer of Cue Biopharma about the company’s initiatives in the development of immune-based biological compounds for the treatment of cancers and autoimmune diseases. Image from Cue Biopharma.

Protein 98

Protein Engineer Immune Response In-Vivo 98

pharmaphorum

JUNE 15, 2021

The pandemic’s disruption galvanised the biopharma industry into unprecedented action, demonstrating what’s possible when the global scientific community collaborates in exceptional ways and public-private partnerships drive innovation to address a common need. But there is a silver lining. These will all help pay for New Science. .

Clinical Trials 90

Clinical Trials Clinical Trials Development Marketing 90

The Pharma Data

MAY 5, 2021

. Esker, a new biotech startup, launches with plans to make targeted immune drugs ( BioPharma Dive ). AbbVie’s Humira regains top pharma TV spender spot, while sibling brands Rinvoq and Skyrizi tag along ( Fierce ). Pfizer ups COVID-19 vaccine revenue estimates ( BioPharma Reporter ).

Vaccination 52

Vaccination Vaccine Gene Therapy Contract Packaging 52